echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Navumab plus docetaxel significantly prolongs survival in patients treated with ICI and NSCLC

    Clin Cancer Res: Navumab plus docetaxel significantly prolongs survival in patients treated with ICI and NSCLC

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The addition of cytotoxic chemotherapy to immune checkpoint inhibitors (ICI) enhances antitumor effects


    The study recruited patients with histologically definitive diagnosis of stage IIIB/IIIC/IV or postoperative recurrence who had previously received first- or second-line chemotherapy and were randomly divided into two groups



    A total of 128 patients (64 in each group) were enrolled in the overall analysis population



    Hematoxicity and gastrointestinal adverse reactions when navumab is combined with docetaxel are more common


    Overall, although toxicity is slightly elevated, the addition of docetaxel to navumab significantly prolongs the overall survival and progression-free survival of patients with ICI who have previously been treated with ICI


    Original source:

    Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.